skip to Main Content

TreatSMA and charity meetings

  • 22 March 2017

TreatSMA had a meeting today with SMA Support UK and The SMA Trust due to the current meetings being held by EMA and their decision expected to be made very soon.

Read More

Biogen update on efficacy of nusinersen

  • 26 February 2017

In infants with spinal muscular atrophy (SMA), treatment with Spinraza (nusinersen), the first FDA-approved drug for SMA, reduces the risk of death or permanent ventilation, according to new results from the Phase 3 ENDEAR study (NCT02193074).

Read More

European procedure for registration of medicines

  • 20 February 2017

The evaluation of medicines in the EU can be through single national submissions (in the first instance then a mutual review lead by the country who made the first assessment) but in the case of medicines of high importance like…

Read More
Back To Top